Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Kaiser

Showing results (1-10 of 216) with videos related to

Pageof 22
Sort By:
International Journal of Cardiology|December 4, 2017
Prasugrel vs clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness analysis from the BASKET-PROVE cohorts - Response to the letter to the EditorBastian Wein, Christoph Kaiser
Herz|July 4, 2007
[Increased rate of stent thrombosis with DES]Christoph Kaiser, Matthias Pfisterer
European Heart Journal|February 19, 2014
Drug-eluting stents with biodegradable polymers: are enough data in for a final assessment?Matthias Pfisterer, Christoph Kaiser
Circulation|December 20, 2011
No one-size-fits-all: A tailored approach to antithrombotic therapy after stent implantationMatthias Pfisterer, Christoph Kaiser, Raban Jeger
Epilepsia|September 30, 2009
Head nodding syndrome and river blindness: a parasitologic perspectiveChristoph Kaiser, Sébastien Pion, Michel Boussinesq
Expert Opinion on Drug Delivery|January 11, 2020
Drug-coated balloons in cardiovascular disease: benefits, challenges, and clinical applicationsThomas Nestelberger, Christoph Kaiser, Raban Jeger
Annals of Translational Medicine|December 30, 2017
River blindness goes beyond the eye: autoimmune antibodies, cross-reactive with <i>Onchocerca volvulus</i> antigen, detected in brain of patients with Nodding syndromeChristoph Kaiser, Sébastien D S Pion
The New England Journal of Medicine|April 2, 2015
Duration of dual antiplatelet therapy after drug-eluting stentsMatthias Pfisterer, Christoph Kaiser, Raban Jeger
Evidence-Based Cardiovascular Medicine|March 15, 2006
Paclitaxel-eluting stents appear to reduce revascularisation in people with long lesionsChristoph Kaiser, Matthias Pfisterer, Debbie Singh
Swiss Medical Weekly|September 2, 2011
Drug-eluting coronary stents in clinical practice: lessons from the «BAsel Stent Kosten-Effektivitäts Trials» (BASKET). A review of the BASKET trialsMatthias Pfisterer, Fabian Nietlispach, Raban Jeger, et al.
Pageof 22

Showing results (1-10 of 216) with videos related to

Sort By:
Pageof 22
International Journal of Cardiology|December 4, 2017
Prasugrel vs clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness analysis from the BASKET-PROVE cohorts - Response to the letter to the EditorBastian Wein, Christoph Kaiser
Herz|July 4, 2007
[Increased rate of stent thrombosis with DES]Christoph Kaiser, Matthias Pfisterer
European Heart Journal|February 19, 2014
Drug-eluting stents with biodegradable polymers: are enough data in for a final assessment?Matthias Pfisterer, Christoph Kaiser
Circulation|December 20, 2011
No one-size-fits-all: A tailored approach to antithrombotic therapy after stent implantationMatthias Pfisterer, Christoph Kaiser, Raban Jeger
Epilepsia|September 30, 2009
Head nodding syndrome and river blindness: a parasitologic perspectiveChristoph Kaiser, Sébastien Pion, Michel Boussinesq
Expert Opinion on Drug Delivery|January 11, 2020
Drug-coated balloons in cardiovascular disease: benefits, challenges, and clinical applicationsThomas Nestelberger, Christoph Kaiser, Raban Jeger
Annals of Translational Medicine|December 30, 2017
River blindness goes beyond the eye: autoimmune antibodies, cross-reactive with <i>Onchocerca volvulus</i> antigen, detected in brain of patients with Nodding syndromeChristoph Kaiser, Sébastien D S Pion
The New England Journal of Medicine|April 2, 2015
Duration of dual antiplatelet therapy after drug-eluting stentsMatthias Pfisterer, Christoph Kaiser, Raban Jeger
Evidence-Based Cardiovascular Medicine|March 15, 2006
Paclitaxel-eluting stents appear to reduce revascularisation in people with long lesionsChristoph Kaiser, Matthias Pfisterer, Debbie Singh
Swiss Medical Weekly|September 2, 2011
Drug-eluting coronary stents in clinical practice: lessons from the «BAsel Stent Kosten-Effektivitäts Trials» (BASKET). A review of the BASKET trialsMatthias Pfisterer, Fabian Nietlispach, Raban Jeger, et al.
Pageof 22